Results 21 to 30 of about 31,394 (214)

A Novel Combination Therapy Using Rosuvastatin and Lactobacillus Combats Dextran Sodium Sulfate-Induced Colitis in High-Fat Diet-Fed Rats by Targeting the TXNIP/NLRP3 Interaction and Influencing Gut Microbiome Composition

Pharmaceuticals, 2021
Inflammasome targeting and controlling dysbiosis are promising therapeutic approaches to control ulcerative colitis. This report is the first to investigate the mechanisms underlying the coloprotective effects of rosuvastatin and Lactobacillus and their ...
S. Saber, E. A. Abd El-Fattah, Galal Yahya, N. Gobba, Abdalkareem Omar Maghmomeh, Ahmed E. Khodir, A. Mourad, A. Saad, Hager G. Mohammed, N. A. Nouh, A. Shata, Noha A. Amin, Magdy Abou El-Rous, S. Girgis, E. El-Ahwany, E. Khalaf, A. El‐kott, A. El-Baz   +17 more
semanticscholar   +1 more source

Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria

Journal of the American Society of Nephrology, 2021
Significance Statement Despite reports of hematuria and proteinuria with rosuvastatin use at the time of its approval by the US Food and Drug Administration (FDA), current labeling mentions dose reduction (maximum daily dose of 10 mg) only for patients ...
Jung-Im Shin, Derek M. Fine, Y. Sang, Aditya L. Surapaneni, Stephan C. Dunning, Lesley A. Inker, Thomas D. Nolin, Alexander R. Chang, Morgan E. Grams   +8 more
semanticscholar   +1 more source

Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects

Фармакокинетика и Фармакодинамика, 2022
Introduction. The advantages of fixed-dose combination losartan + amlodipine + rosuvastatin compared to mono-drugs and two-component combinations are to increase the therapeutic efficacy, to reduce the cost of the product and to make the drug easier to ...
A. L. Khokhlov, D. Yu. Grebenkin, E. K. Faeva, V. I. Kazey, A. A. Khokhlov, A. E. Miroshnikov, O. V. Lebedeva   +6 more
doaj   +1 more source

Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials.

Cardiovascular Research, 2021
AIMS To examine the association between rosuvastatin and VTE risk, and whether effects vary in different subpopulations stratified by key demographic, cardiovascular disease (CVD) risk factors and other risk factors associated with VTE.
P. Joseph, R. Glynn, E. Lonn, C. Ramasundarahettige, J. Eikelboom, Jean G Macfadyen, P. Ridker, S. Yusuf   +7 more
semanticscholar   +1 more source

Rosuvastatin Attenuates Rheumatoid Arthritis-Associated Manifestations via Modulation of the Pro- and Anti-inflammatory Cytokine Network: A Combination of In Vitro and In Vivo Studies

ACS Omega, 2021
The current investigation employed rosuvastatin for evaluation as an antiarthritic agent by in vitro and in vivo studies. In vitro studies comprised egg albumin and bovine serum albumin protein denaturation assays along with membrane stabilization assays,
Sumera Qasim, Alamgeer, Saima Kalsoom, M. Shahzad, I. Bukhari, Fahim Vohra, Sibtain Afzal   +6 more
semanticscholar   +1 more source

NanoUPLC-QTOF-MS/MS Determination of Major Rosuvastatin Degradation Products Generated by Gamma Radiation in Aqueous Solution

Pharmaceuticals, 2021
Rosuvastatin, a member of the statin family of drugs, is used to regulate high cholesterol levels in the human body. Moreover, rosuvastatin and other statins demonstrate a protective role against free radical-induced oxidative stress.
Lucija Dončević, Ema Svetličić, Amela Hozić, Branka Mihaljević, Dorota Jarmużek, Ivana Tartaro Bujak, Donata Pluskota-Karwatka, Luka Ozdanovac, Iva Džeba, Mario Cindrić   +9 more
doaj   +1 more source

Evaluation of rosuvastatin-induced QT prolongation risk using real-world data, in vitro cardiomyocyte studies, and mortality assessment

Scientific Reports, 2023
Drug-induced QT prolongation is attributed to several mechanisms, including hERG channel blockage. However, the risks, mechanisms, and the effects of rosuvastatin-induced QT prolongation remain unclear.
Yeryung Koo, Sung-Ae Hyun, Byung Jin Choi, Yujeong Kim, Tae Young Kim, Hong-Seok Lim, Joung-Wook Seo, Dukyong Yoon   +7 more
doaj   +1 more source

Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome

Diseases, 2018
Adipose tissue-derived serine protease inhibitor (vaspin), which has endocrine and local roles in atherosclerosis growth, is also synthesized by adipose tissue; it was found that vaspin was negatively correlated with blood pressure in obese patients ...
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Ali K. Al-Buhadilly   +2 more
doaj   +1 more source

A heparin–rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis

Journal of Nanobiotechnology, 2021
Background An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment.
Ying-jun Liu, Peixi Liu, Yaying Song, Sichen Li, Yuan Shi, Kai Quan, Guo-long Yu, Peiliang Li, Qingzhu An, Wei Zhu   +9 more
semanticscholar   +1 more source

The influence of the intestinal microflora to the efficacy of Rosuvastatin

Lipids in Health and Disease, 2018
Background Intestinal microflora has been shown to play essential roles in the clinical therapies of metabolic diseases. The present study is aiming to investigate the potential roles and mechanisms of how intestinal microflora mediates lipid-reduction ...
Lijun Wang, Yang Wang, Hongwei Wang, Xue Zhou, Xianjing Wei, Zezhou Xie, Zhipeng Zhang, Keke Wang, Jianjun Mu   +8 more
doaj   +1 more source